government mandate
OpenAI suggests voluntary AI standards, not government mandates, to ensure AI safety
Fox News contributor Joe Concha joins "Fox & Friends First" to discuss Elon Musk's warning that AI could threaten elections and his concerns on the declining birth rate. The top lawyer for OpenAI, the company that developed ChatGPT, argued that the best way to regulate artificial intelligence is not to start with government mandated rules and regulations but to allow the companies themselves to set standards that ensure AI is used safely and responsibly. OpenAI General Counsel Jason Kwon made that argument during a Tuesday panel discussion in Washington, D.C., which was hosted by BSA/The Software Alliance, even as he acknowledged that AI is developing so quickly that it can often lead to unexpected results that companies quickly need to rein in. Still, when asked what his message to policymakers was, Kwon recommended voluntary, industry-led standards for AI, calling for a tactic that many companies in most industries tend to favor over government mandates. The top lawyer at OpenAI, run by CEO Sam Altman, above, said this week that the company recommends voluntary industry standards to regulate AI, not government mandates.
- Law (1.00)
- Government (1.00)
- Media > News (0.55)
- Information Technology > Artificial Intelligence > Natural Language > Large Language Model (1.00)
- Information Technology > Artificial Intelligence > Natural Language > Chatbot (1.00)
- Information Technology > Artificial Intelligence > Machine Learning > Neural Networks > Deep Learning > Generative AI (1.00)
- Information Technology > Artificial Intelligence > Issues > Social & Ethical Issues (1.00)
- North America > United States > Ohio > Franklin County > Columbus (0.40)
- North America > United States > Illinois > Cook County > Chicago (0.04)
- North America > United States > Colorado (0.04)
- Education (0.69)
- Information Technology > Services (0.46)
- Health & Medicine > Therapeutic Area > Immunology (0.31)
- Health & Medicine > Pharmaceuticals & Biotechnology (0.31)